Executive Summary of Avotres Inc. Investment Opportunity

Impacting about 5-7% of US population, autoimmune disease (AID) is a cluster of more than 80 conditions with many lacking effective therapies. There is limited treatment satisfaction for many cancers due to low survival rate. Patients with transplantations require the lifelong use of immunosuppressants, leading to a compromised immune system. Taken together there are significant unmet medical needs in these therapeutic areas.

Holding exclusive global rights to the IP originated from Columbia University, Avotres has discovered a novel MoA targeting a CD8+ Treg pathway that enables the restoration of self-tolerance in immune system, hence stopping the self-attack which is the common root cause for many AID. In addition, Avotres has unveiled a new immuno-oncology (I-O) target for certain types of cancers. These discoveries have shaped the Avotres pipeline.

There are two more assets in Avotres pipeline. At preclinical stage, AVT002 is an antibody-based therapy of a novel I-O target with potential to reduce early/late stage cancer recurrence and as a synergistic combination therapy with checkpoint inhibitors and beyond. We expect to file IND for AVT002 in two years and anticipate a peak sale at $5-10 billion for AVT002. Also included is AVT-Dx001, a diagnostic test for early detection of AID. 

Our products and technology are protected by a family of patents covering main markets in the world, some of them pending and some already granted.  

Impacting about 5-7% of US population, autoimmune disease (AID) is a cluster of more than 80 conditions with many lacking effective therapies.  No current therapies on the market treat the root cause of the autoimmune diseases, instead, they primarily treat the symptoms with some have some degree of diseases-modifying nature.  There is no cure.  Despite that, the current market size of autoimmune diseases is around $100+ billion US dollars/year.  

There is limited treatment satisfaction for many cancers due to low survival rate. The current market size of autoimmune diseases well exceeds $100+ billion US dollars/year.  

Patients with transplantations require the lifelong use of immunosuppressants, leading to a compromised immune system. 

Taken together there are significant unmet medical needs in these therapeutic areas.

Avotres was founded in December 2016 in New York City, and started official operations in January 2018.  It is currently located in Cedar Knolls, New Jersey, USA.  

Avotres has a world class management and advisors team including the primary Columbia University inventor as its CSO. 

Avotres CEO is a recognized leader in the mainstream US life science industries.  He is one of the very few Chinese-Americans who were able to break the “glass ceiling” in the US.  He is a seasoned professional in building companies and teams, has his core experience in drug development and commercialization strategies, and is a recognized world-class thought leader in personalized medicine strategy.